MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx^® vs. SANTYL^® within the ChronEx Phase II Randomized Controlled Study

MediWound, Ltd announced the results of head-to-head comparison analyses of EscharEx, the Company’s lead asset in development for chronic wounds, to collagenase SANTYL ointment, approved by the FDA for debriding chronic dermal ulcers.